Greg Durm retweeted
Excited to continue to see this workshop grow each year. A great opportunity for fellows and early faculty, focusing on ways to fund investigator initiated trials. Applications currently open for next cohort - link in article!
aaci-cancer.org/News-The-Jam…
Greg Durm retweeted
What are plenary sessions for ASCO 2026 ?
Titles are just out
Watch out 🙂👇 @ASCO #asco2026 @Alfdoc2 @APassaroMD @dr_yakupergun @OncBrothers @OncoAlert @MedwatchKate @FordePatrick @DrJNaidoo @MyriamChalabi @DrChoueiri
Greg Durm retweeted
Terrific dinner with colleagues and friends before the @IndianaUniv Lung Cancer Symposium! Thanks to Dr Durm @gdurm and IU for the invitation and being such wonderful hosts! Looking forward to a day of learning tomorrow! #lcsm
Greg Durm retweeted
New #JITC article: Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081 bit.ly/44WS2xZ
@gdurm @HirvaMamdani @SalmaJabbour1 @AparGanti @ShadiaJalal @DrJNaidoo
@maryjofidlerMD @LealTiciana @DrLFeldman1
Greg Durm retweeted
Randomized Ph II trial: 6m consolidation nivo (N) or ipi/nivo (I/N) in stage III unresectable NSCLC @jitcancer
- 18m-PFS 65.5% N, 66.3% I/N
- mOS 32m, NR
- g3+ TRAE 18.5% v 29.4%
Congrats @gdurm @BigTenCRC 🏆, pleased to contribute as @HopkinsThoracic PI
jitc.bmj.com/content/13/7/e0…
Greg Durm retweeted
Dr. Anita Turk discusses Advances in Biomarker Based Management in Mets Colorectal Ca @IUCancerCenter @IUHemOnc @anita_turk
Greg Durm retweeted
Dr. Rebecca Hassoun presenting outcomes with salvage high dose chemo and transplant in relapsed GCT based on radiographic vs tumor marker progression @rebeccahassoun @IUCancerCenter @IUHemOnc
Greg Durm retweeted
Indiana University reception at #ASCO2025 . Proud to work with a fantastic group of past, present, and future colleagues @IUCancerCenter @IUHemOnc @IU_UroOnc @rabonour1 @ChrisSweens1 @Noah_Onc @ASCOPres @ahmadalhader @gdurm @hannawants2ELCN @JenSchwartzIUSM
Greg Durm retweeted
Why do people get ALK+ lung cancer? Why do some respond well to treatments and others less so? How can we better treat this disease?
Lung cancer research is not just about answering these key questions, but about hope.
It's why Dr @AngelQinMD believes #MoreResearchMoreLife.
Greg Durm retweeted
ctDNA+ in consolidation IO trial (BTCRC 16-081) associates with outcomes in stage III unresectable NSCLC @JTOonline:
- Tumor-informed ctDNA MRD analysis post CRT, C2D1 IO, & post 6m of IO
- ctDNA+ assoc with ⬇️PFS at all timepts
@OncoAlert @gdurm #LCSM
jto.org/article/S1556-0864%2… – at Dublin City, Ireland
Greg Durm retweeted
When you’re given a platform, you use it.
Women: You can be great mothers and have successful careers. These are not mutually exclusive.
Huge thanks to the UCSD Medical School graduating class for inviting me to speak this year!
#womeninmedicine
Greg Durm retweeted
LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 @LeciaSequist
Greg Durm retweeted
Having seen LAURA, Dr Jayakrishnan presents retrospective ALK+ unresectsble st3 outcomes by consolidation Rx ost. Chemo-RT. ALK TKI rwPFS huge va no consolidation. Translates to OS benefit.
Reinforces @LeciaSequist message that TKI consolidation important for AGA NSCLC #ASCO24
Greg Durm retweeted
#ADRIATIC - new standard of care in #SCLC, where we have not seen an advance in >2 decades. Truly historic data with use of immunotherapy consolidation #LungPlenary @DavidRSpigel @LaurenByersMD
@ASCO #ASCO24 @OncoAlert
Greg Durm retweeted
EVOKE-01 from #ASCO24 @JCO_ASCO. Phase III study of the Trop2 ADC sacituzumab govitecan vs docetaxel in NSCLC post chemo/IO. Did not meet OS endpoint (11.1 vs 9.8m, HR 0.84) but numeric improvement in squamous & non-sq. If nonresponsive to IO, OS HR 0.75
ascopubs.org/doi/10.1200/JCO…
Greg Durm retweeted
CROWN results from #ASCO24 @JCO_ASCO: phase III 1L lorlatinib vs crizotinib in #ALK NSCLC. With 5y median f/u, median PFS not reached. 5y PFS rate 60% with lorlatinib (8% with crizotinib), median time to intracranial progression NR vs 16.4m (HR 0.06).
ascopubs.org/doi/10.1200/JCO…
Greg Durm retweeted
POP QUIZ: Is this a waterfall plot for a new lung cancer TKI? Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. @MDAndersonNews Thank you to the study team and all of our investigators, patients and families. @ASCO #ASCO24
